75498 Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices 

letter to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of 4-Anilino-NPhenethyl-4-Piperidine (ANPP) (8333), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to use this 

controlled substance in the manufacture 

of another controlled substance. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than February 1, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30360 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 8, 2010, 

Agilent Technologies, 25200 

Commercentre Drive, Lake Forest, 

California 92630–8810, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Phencyclidine (7471) .................... II 

1-piperidinocyclohex- ....................

anecarbonitrile (8603) ..................

II 

Benzoylecgonine (9180) ............... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances for use in diagnostic 

products. 

Agilent Technologies submitted this 

application because, effective May 14, 

2010, Varian, Inc., located at 25200 

Commercentre Drive, Lake Forest, 

California 92630–8810, became a 

wholly-owned subsidiary of Agilent 

Technologies. Varian, Inc.’s legal 

existence as a corporation and as a DEA 

registrant as a bulk manufacturer will 

eventually cease and Agilent 

Technologies will take over all of Varian 

Inc.’s activities with regard to controlled 

substances, requiring possession of a 

DEA registration as a bulk manufacturer 

issued to Agilent Technologies. 

Presently, Agilent Technologies’ 

activities with regard to controlled 

substances will be exactly the same as 

performed by Varian, Inc. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR § 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than February 1, 2011. 

Dated: November 18, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30358 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated May 28, 2010 and 

published in the Federal Register on 

June 8, 2010, (75 FR 32506), Boehringer 

Ingelheim Chemicals, Inc., 2820 N. 

Normandy Drive, Petersburg, Virginia 

23805–9372, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers for formulation 

into finished pharmaceuticals. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Boehringer Ingelheim Chemicals, Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Boehringer Ingelheim 

Chemicals, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30352 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Mine Safety and Health Administration 

Petitions for Modification of Existing 

Mandatory Safety Standards 

AGENCY: Mine Safety and Health 

Administration (MSHA), Labor. 

ACTION: Notice. 

SUMMARY: Section 101(c) of the Federal 

Mine Safety and Health Act of 1977 and 

30 CFR part 44 govern the application, 

processing, and disposition of petitions 

for modification. This notice is a 

summary of petitions for modification 

filed by the parties listed below to 

modify the application of existing 

mandatory safety standards published 

in Title 30 of the Code of Federal 

Regulations. 

DATES: All comments on the petitions 

must be received by the Office of 

Standards, Regulations and Variances 

on or before January 3, 2011. 

ADDRESSES: You may submit your 

comments, identified by ‘‘docket 

number’’ on the subject line, by any of 

the following methods: 

1. Electronic Mail: zzMSHAcomments@dol.gov. Include the docket 

number of the petition in the subject 

line of the message. 

2. Facsimile: 1–202–693–9441. 

3. Regular Mail: MSHA, Office of 

Standards, Regulations and Variances, 

1100 Wilson Boulevard, Room 2350, 

Arlington, Virginia 22209–3939, 

Attention: Patricia W. Silvey, Director, 

Office of Standards, Regulations and 

Variances. 

mstockstill on DSKH9S0YB1PROD with NOTICES